Vedanta Biosciences to Participate in the JMP Securities Life Sciences Conference

Rhea-AI Summary

Vedanta Biosciences, a clinical-stage company, announced that CEO Bernat Olle will speak at the JMP Securities Life Sciences Conference on June 16, 2022, at 11:30 a.m. ET in New York. The company focuses on developing a new category of oral therapies based on defined bacterial consortia from the human microbiome to treat conditions such as C. difficile infection and inflammatory bowel diseases. Vedanta controls a significant patent portfolio and boasts expertise in bacterial consortium design, with a belief in their pioneering research in this emerging field.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that Bernat Olle, Ph.D., Chief Executive Officer of Vedanta Biosciences, will participate in a fireside chat at the JMP Securities Life Sciences Conference being held June 15-16, 2022 at the Lotte New York Palace in New York, NY.

The JMP Securities Life Sciences Conference
Date: Thursday, June 16, 2022
Time: 11:30 a.m. ET

About Vedanta Biosciences
Vedanta Biosciences is leading the development of a potential new category of oral therapies based on defined consortia of bacteria isolated from the human microbiome and grown from pure clonal cell banks. The company’s clinical-stage pipeline includes product candidates being evaluated for the treatment of high-risk C. difficile infection, inflammatory bowel diseases, food allergy, liver disease, and cancer. These investigational therapies are grounded in pioneering research – published in leading journals including Science, Nature, and Cell – to identify beneficial bacteria that live symbiotically within the healthy human gut, fight pathogens and induce a range of potent immune responses. Vedanta Biosciences controls a foundational portfolio of more than 45 patents and has built what it believes is one of the largest libraries of bacteria derived from the human microbiome. Proprietary capabilities include deep expertise in consortium design, vast datasets from human interventional studies, and CGMP-compliant manufacturing of oral Live Biotherapeutic Product (LBP) candidates containing pure, clonally-derived bacterial consortia in powdered form. Vedanta Biosciences was founded by PureTech Health (Nasdaq: PRTC, LSE: PRTC) and a global team of scientific co-founders who pioneered the modern understanding of the cross-talk between the microbiome and the immune system.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220608005359/en/

Media

Nichole Sarkis

+1 774 278 8273

nichole@tenbridgecommunications.com

Investors

Chris Brinzey

+ 1 617 835 9304

Chris.Brinzey@westwicke.com

Source: Vedanta Biosciences

FAQ

When is the JMP Securities Life Sciences Conference featuring Vedanta Biosciences CEO?

The JMP Securities Life Sciences Conference will take place on June 16, 2022, at 11:30 a.m. ET.

What is Vedanta Biosciences known for?

Vedanta Biosciences is developing oral therapies based on defined bacterial consortia for various medical conditions.

What diseases is Vedanta Biosciences targeting with its therapies?

The company's therapies aim to treat high-risk C. difficile infection, inflammatory bowel diseases, and more.

Who is the CEO of Vedanta Biosciences?

Bernat Olle, Ph.D., is the CEO of Vedanta Biosciences.

What is the stock symbol for Vedanta Biosciences?

Vedanta Biosciences' parent company, PureTech Health, is listed under the stock symbol PRTC on Nasdaq and LSE.